Capstan Therapeutics

Next month Capstan will attend the 45th Annual Goldman Sachs Global Healthcare Conference. More in today’s release: https://lnkd.in/e7b_mZUK

Next week, two of Capstan’s Co-Founders Bruce Levine, Ph.D., and Haig Aghajanian, Ph.D., will attend ISCT, International Society for Cell & Gene Therapy 2024 and join other industry leaders in various sessions focused on both enabling gene editing platforms for novel in vivo and ex vivo therapeutics, and the benefits of mRNA therapeutics. At Capstan, we are developing targeted in vivo RNA-based therapies to create the next generation of transformative therapies.

Tomorrow our Director of RNA Platform Technology Development, Daiki Matsuda, Ph.D., will give a presentation at the 3rd Annual Next Generation RNA Therapeutics Summit by World RNA Series. Dr. Matsuda will discuss the benefits of our RNA-based targeted LNP platform that enables in vivo engineering of immune cells to target a broad range of disease areas, including #autoimmune disorders, #oncology, and #fibrosis. 

“That process [in vivo] should make it much, much simpler and cheaper to deliver CAR-T. With conventional CAR-T therapies, patients have to undergo chemotherapy to destroy their existing T cells. But with in vivo CAR-T, this step isn’t necessary. And because these therapies don't require any cell manipulation outside the patient's body, you could take it in an outpatient clinic. You wouldn’t need specialized centers,” says Priya Karmali, Ph.D., our Chief Technology Officer, in this piece from MIT Technology Review by Cassandra Willyard.   Read more about the potential that in vivo CAR T has on the future, as well as the overall cost, of the therapeutic treatment landscape in the article below.

Targeted lipid nanoparticles (tLNP), the foundation of our therapeutic platform for targeted in vivo delivery of RNA to specific cell types, are one of the most promising new therapeutic modalities. Next week at the Festival of Biologics, our Associate Director, Antibody CMC QC (Qian-Chen) Yong will present on general considerations when selecting a targeting antibody, a critical component for the tLNP.

At Capstan, we are committed to building a company that represents the multitude of voices, values, and perspectives that is reflective of our world today – including celebrating various holidays throughout the year. Last month, we honored Lunar New Year, Easter, Holi, Nowruz, Purim, the beginning of Ramadan, and Saint Patrick’s Day as a team by decorating, bringing in various foods, and participating in activities and traditions together as a team.   Want to be a Capstaneer? View our open positions on our website: https://lnkd.in/eiU8hT7y

We are thrilled to welcome Holly Chrzanowski Winter as our new Senior Vice President, People and Culture, to support the continued development of our rapidly growing team and vibrant culture.    Holly is a seasoned HR professional, bringing over two decades of experience in supporting the growth and success of biotech companies that foster a positive, dynamic, and diverse work environment.    Welcome, Holly!

#ICYMI, last week we announced an oversubscribed Series B financing of $175 million, which will support the advancement of our lead in vivo CAR-T program, CPTX2309, through clinical proof-of-concept studies for #autoimmune disorders. Thank you, NYSE, for featuring us on the trading floor.   Read more about the announcement here: https://lnkd.in/eN5WcfkX

This week Capstan CSO and EVP of R&D, Adrian Bot, M.D., Ph.D., will participate in a fireside chat at the 2nd Annual H.C. Wainwright & Co., LLC Cell Therapy Virtual Conference, where he will discuss our mission to multiply the possibilities for patients through our targeted in vivo RNA-based approach.

It’s an exciting time to be on Team Capstan as we look to advance our in vivo CAR-T lead program, CPTX2309, using the proceeds of our recently announced oversubscribed Series B financing: https://lnkd.in/eN5WcfkX   We are hiring at multiple levels across various disciplines including in vitro pharmacology, analytical development, formulation & process development, and more.   Interested in joining our creative, collaborative team committed to pioneering a new frontier of medicine? Read more about our open positions and apply here: https://lnkd.in/eiU8hT7y